1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.
Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 13, 30, 26, 6, 125, 44 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 36 and 13 molecules, respectively.
Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionAmyotrophic Lateral Sclerosis - Overview
Amyotrophic Lateral Sclerosis - Therapeutics Development
Amyotrophic Lateral Sclerosis - Therapeutics Assessment
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
Amyotrophic Lateral Sclerosis - Drug Profiles
Amyotrophic Lateral Sclerosis - Dormant Projects
Amyotrophic Lateral Sclerosis - Discontinued Products
Amyotrophic Lateral Sclerosis - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by 1st Bio Therapeutics Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Above and Beyond Concierge Therapeutics LLC, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by AC Immune SA, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Aclipse One Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Aclipse Therapeutics LLC, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by AcuraStem Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Adare Pharma Solutions, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Affichem SA, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by AgoneX Biopharmaceuticals Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by AI Therapeutics Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by AL-S Pharma AG, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by AlphaCognition Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Alsonex Pty Ltd, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Amicogen Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Amylyx Pharmaceutical Corp, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Anima Biotech Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Ankar Pharma SL, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Annexon Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Apellis Pharmaceuticals Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Apic Bio Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Apogenix AG, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Applied Genetic Technologies Corp, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Aquilus Pharmaceuticals Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Relmada Therapeutics Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by ReoStem LLC, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Retrotope Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Revalesio Corp, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Samus Therapeutics Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Sangamo Therapeutics Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Seelos Therapeutics, Inc., H2 2020
- Amyotrophic Lateral Sclerosis - Pipeline by Seneca Biopharma Inc, H2 2020
- Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2020
- Amyotrophic Lateral Sclerosis - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1st Bio Therapeutics Inc
- AB Science SA
- Above and Beyond Concierge Therapeutics LLC
- AC Immune SA
- Aclipse One Inc
- Aclipse Therapeutics LLC
- AcuraStem Inc
